Wed., October 29, 2008 | | Archives | Advertising | Your Account | CHI Conferences |  Subscribe |

Industry Trends

U.S. Generic Drug Market Outlook to 2012
By Mark P. Mathieu

Since drugs with $50 billion on 2007 U.S. sales are scheduled to lose patent/exclusivity protection in 2008 – 2010, the three-year period presents formidable obstacles for the pharmaceutical industry. Marketing exclusivity … Read more

Sales Contacts
For advertising information contact: 

Tom Loughran
Regional Sales Manager, Advertising Sales -Midwest, South Eastern US, Europe

Contact the Editor
Alissa PohPharmaWeek welcomes your feedback. Please contact Alissa Poh for editorial inquiries.

Link to Us! 
You are welcome to link to articles on our website. Contact Catherine Varmazis for details.

e-Prints & Reprints 
To post a full article from PharmaWeek or Bio-IT World on your website (not just a link), or for paper reprints, please contact:
Ashley Zander
The YGS Group
717-399-1900 ext.125

Dear Colleague,
Welcome to this week's eNewsletter covering breaking R&D news, business insights, and a feature on North Carolina's Research Triangle Park.


The Research Triangle Park: 50 Years of Innovation
By Alissa Poh

There’ll be much feasting and merrymaking next January – big administration changes aside, that is – when North Carolina’s Research Triangle Park celebrates its golden anniversary. And its leaders will also have opportunities galore to reflect on various trials and triumphs that have marked the last several decades, since RTP’s inception in 1959.
“It [RTP] is truly an ongoing experiment in economic development,” says Kevin Johnson, vice president for business development at the park. “Our major universities [Duke; UNC-Chapel Hill; NC State] existed in the 1950s; all this concentration of talent was here. What wasn’t here, then, was an economic base for which these students could have a reasonable chance of earning a living. So they’d wind up in Boston, in New York – we had no means of capturing our talent here in North Carolina.” More


Genzyme's Campath May Slow MS
BusinessWeek [Oct 22] Campath, a Genzyme drug already approved for leukemia, may turn out to be one of the most effective treatments for multiple sclerosis, and is the first medication to show potential for reversing the disease, according to a recent study in the New England Journal of Medicine. More

FDA Panel Backs Genzyme's Mass-Produced Myozyme
Reuters [Oct 21] The FDA will approve a mass-produced version of Myozyme, Genzyme’s drug against Pompe disease, as long as there are postmarketing studies to ensure its safety and efficacy. More

Merck's Free Radical
Forbes [Oct 22] Cancer drugs don't help 75% of the people who take them. Merck cancer guru Stephen Friend says he can use science to end the crapshoot, by creating a giant, open-to-the-public database that includes every cancer drug and every patient, and how that patient is doing. More

A 'Negative' Label For Drug Makers
Forbes [Oct 27] In a recent Wall Street Journal article about a drug company's alleged suppression of unfavorable findings in clinical trials, the reporter repeatedly used terms like "negative studies," "negative outcomes" and "negative results." But nowhere did he explain that, in the context of scientific and clinical experiments, the term "negative" has a meaning very different from the common usage. More

Researchers Find Trigger For Killer Protein
Yahoo! News [Oct 22] Scientists at the Dana-Farber Cancer Institute have found a way to switch on the apoptotic protein Bax, by making a peptide that fits perfectly into the trigger mechanism. This discovery could be used to develop drugs that turn on or turn off cell death in human diseases such as cancer. More

Compugen Announces Discovery Platform to Identify Viral Peptides
MarketWatch [Oct 23] Compugen has developed a new Viral Peptides Discovery Platform designed to identify peptides from viral genomes for potential human therapeutic use against inflammatory and immune related diseases. More

Safety Issues For One in Four Biologics
Boston Globe [Oct 22] Nearly a fourth of widely used new-generation biological drugs for several common diseases produce serious side effects that lead to safety warnings soon after they go on the market, the first major study of its kind found. More


Merck Plans to Cut 12% of Work Force as Its Sales and Profit Fall
New York Times [Oct 22] Hurt by declining sales of some of its biggest drugs and vaccines, Merck plans on cutting 7,200 more jobs, or more than 12% of its work force, its second revamping in three years. More

Potential Roadblock For ImClone Deal
Forbes [Oct 27] Although it spent weeks teasing investors about the identity of its suitor, ImClone failed to satisfy all of its shareholders that a $6.5 billion bid from Eli Lilly fairly values the biotech business. More

Sanofi’s Acomplia Pulled From EU Market
Reuters [Oct 23] European authorities have asked French drug company Sanofi to withdraw its anti-obesity drug Acomplia from the market, over links to mental disorders. More

The Shrinking Drug Industry
Forbes [Oct 22] While various Big Pharma companies are releasing earnings that exceed Wall Street expectations, this has a great deal to do with company control of costs. Fewer new drugs are reaching the market; the average new drug is said to be generating lower sales; existing blockbusters are facing generic competition. The end result: a drug industry that is shrinking in size. More

A Silver Lining For Pharmaceuticals
The Philadelphia Inquirer [Oct 26] The credit crunch means small companies will be seeking suitors – a good thing as Big Pharma hits a “patent cliff.” More

Pfizer Deals Into Australian Drug Research
BusinessDay [Oct 27] With the capital-raising market for life sciences companies stagnant, Pfizer is playing the part of venture capitalist for promising companies in need of a funding boost. Its vice-president for venture capital, Barbara Dalton, is holding meetings with several Australian biotechs this week, with a view to including them among the six to eight investment deals Pfizer hopes to strike each year. More

Cautious Glaxo Warns of Difficult US Market as Weak Pound Flatters Revenues
The Guardian [Oct 23] A weak pound helped GSK post growth in revenues and earnings per share that exceeded expectations. But on constant exchange rate terms, the company saw a decline of 3% in sales overall and 13% in US sales as many of its products reached the "generic cliff.” More


Boosting the Pipelines: Mother Nature's Resources
PharmaWeek [Oct 22] Legend has it that in northern Greece, villagers used to walk their old, ailing (read: no longer useful) donkeys up a mountain and leave them there, tied to a yew tree. The poor starving beasts would resort to eating the tree’s leaves and bark – and die. Women called it, simply, the ‘donkey tree’; men were more apt to refer to it as the ‘mother-in-law tree.’  And in his book Gallic Wars, Caesar described how, after being roundly defeated by the Roman legions, the barbarian chieftain Catulvolcus committed suicide by drinking tea made from a yew tree extract. 



Memorial Sloan-Kettering Cancer Center - Linux Systems Administrator
MSKCC Bioinformatics Core in Manhattan seeks Linux System
Administrator. Install, configure, update, monitor and troubleshoot HPC cluster, email and web servers. Master's degree and 5 years experience with HPC, network security, Postfix, Apache, Tomcat, Grid Engine, Solaris. Email or #015429. EOE/AA

MedImmune INC. - Associate Director, Development Information Systems
Associate Director, Development Information Systems (Gaithersburg, MD): Responsible for IS strategy for the global Development organization, implementation and oversight of the ongoing projects and support of existing systems.  If you are interested in this position, apply online at and search for Req 01124.

More Life Science Jobs ~ Add a Job Listing



Super Computing ~ November 15-21, Austin, TX 

Fifth Annual Molecular Imaging Week ~November 17-19, 2008, La Jolla, CA

The Next Tool for Healthcare Innovation~Nov 20, 2008 2pm EST A Complimentary Frost & Sullivan eBroadcast

The 4th Annual World Healthcare Innovation and Technology Congress - December 8 – 10, 2008 | Washington, DC

The Association for Laboratory Automation (ALA) presents LabAutomation2009, January 24-28, in Palm Springs, CA. 

TEPR+ 2009 - Feb 1-5, 2009 | Palm Springs, CA

The World Health Care Congress 2nd Annual Leadership Summit on Consumer Connectivity & Web Empowerment | February 23 – 24, 2009-Carlsbad, CA

7th Annual Bio-IT World Conference - April 2009

Storage for Science Seminar Series-See Schedule Here

Barnett Educational Services

Cambridge Healthtech Events

To have your event featured here, contact Lynn Cloonan for more information.

 Email to a Friend 


Alissa Poh 

As you may have surmised, I was recently taken on a whirlwind tour of the Research Triangle Park in NC. Pretty impressive and varied place, from sprawling complexes like those of GSK and Biogen Idec to much smaller facilities where everything (R&D, biomanufacturing) is crammed into one space. I’m planning to give economic development issues more coverage in PharmaWeek – perhaps a regular section, or a special edition every so often providing updates on new facilities, buildings, and job openings (or losses) in various regions. So when RTP was described as “an ongoing experiment in economic development,” I thought it’d be an excellent way to introduce this idea and give readers an overview of the place, at the same time. Expect more stories from the NC region in future issues – but rest assured, I’ll keep them well-spaced so you don’t feel overloaded. Contact me at if you have feedback or suggestions, especially along the economic development line.


Life Science Webcasts from Bio-IT World and Cambridge Healthtech Media Group

Life Science Webcasts

Bio-IT World Expo
Video Highlights

Drug Discovery, Development and Commercialization: Evolving Challenges and Opportunities
Joshua Boger, PhD, president and CEO, Vertex Pharmaceuticals Inc., delivers his keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 2008.
View the Webcast Now.

Personalized Genetics: Advancements and Driving Change
Linda Avey, co-founder of 23andMe, delivers her keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.
View the Webcast Now.

The Future of Personal Genomics
A distinguished panel of personal genomics experts discuss the future of personal genomics at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.  They include Dietrich Stephan (co-founder, Navigenics); George Church (Harvard Medical School);
Jeff Drazen (editor-in-chief, New England Journal Medicine); Fred Ledley (Bentley College); John Halamka (CIO, Harvard Medical School); and Linda Avey (23andMe). Bio-IT World Editor-in-Chief Kevin Davies moderates the discussion.
View the Webcast Now

Bio-IT World's 2009
Best Pract
ices Awards

Entry forms are now available for Bio-IT World’s 2009 Best Practices Awards program. This has long been one of our most successful programs. Last year, there were 56 entries and we awarded 15 prizes at a gala dinner held during the Bio-IT World Conference & Expo in the spring. This year we are hoping to expand those numbers. 
The program is intended to spotlight companies whose use of innovative technologies is making a positive difference in biomedical R&D and drug discovery and development.
Bio-IT World is also making available a free compendium of Best Practice entries from 2008 to help ensure the lessons learned are widely spread. The compendium can be downloaded here.

Meanwhile, get started on this year’s entries. There are nine categories, shown below. The deadline is mid-January 2009. Full details of the entry process and the entry form are available by clicking here.

2009 Best Practices Categories:
*Basic Research & Biological Research
*Drug Discovery & Development
*Clinical Trials & Research
*Translational Medicine
*Personalized Medicine
*IT & Informatics
*Knowledge Management
*Manufacturing & Bioprocessing

All of the entries will be reviewed and ranked by a panel of experts assembled by Bio-IT World editors. Winners will be announced at a dinner ceremony held in Boston in April 2009 in conjunction with the Bio-IT World Conference & Expo. If you have questions, write to 
Insight Pharma Reports

Insight Updates—Kinase Therapeutic Pipelines

Bi-monthly Kinase Insight Update reports provide updated business intelligence on clinical trials, company announcements, research activities, and more from April 2008 to May 2009. More Information 

Featured Content

Managed Innovation, 
Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
sponsored by SAS

Discovery organizations are identifying a lot of promising compounds, but clinical research processes haven't kept pace with timely testing of all those potential therapies. This white paper describes how SAS Drug Development supports true innovation across the clinical trial process.
In this white paper you will learn how to:
~Assemble data to foster better collaboration
~Get up-to-date information during clinical trials
~Make informed decisions earlier in the trial process
Download now


Addressing Life Sciences Constantly Growing Data Challenges Research Environments sponsored by BlueArc

The continued explosion of raw experimental data, the increased use of video, the growingadoption of new data retention practices, and the move to high throughput computational workflows are all placing new demands on the way life sciences organizations store and manage their data.
Download this white paper to learn about:
• Factors driving the data explosion in the life sciences
• New data management issues that must be addressed
• HPC trends that are placing new demands on storage
• Storage solution attributes that address performance, manageability, and energy efficiency. Download now

“Storage for Science – Methods for Managing Large and Rapidly Growing Data Stores in Life Science Research Environments” sponsored by Isilon

Large and rapidly growing stores of file-based and other data are a hallmark of life science research and bioinformatics. Determining how best to manage those data stores has become a significant challenge for Researchers and IT Pros alike.  This paper is intended to:  Provide guidance on the many storage  requirements common to Life Science research;  Explain the evolution of modern storage architectures; Summarize the major data storage architectures currently in use.  Additionally, it will present the Isilon IQ clustered storage product as a strong and flexible solution to those needs. Download now

Microsoft’s BioIT Alliance

Bio-IT World published a special supplement with support from Microsoft and their Alliance members. The supplement provides insight into the activities of the Alliance and their partners. Click here to access the Supplement PDF.

To have your white paper featured here, contact Lynn Cloonan for more information.

                                Healthtech InstitutePublished by Cambridge Healthtech Institute (CHI). Copyright © 2008, all rights reserved. No material may be reproduced electronically or in print without written permission from CHI, 250 First Ave., Needham, MA 02494-2814. For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA; 17601 717-399-1900 ext.125, or email: